Increased Risk of Obesity and Metabolic Dysregulation Following 12 Months of Second-Generation Antipsychotic Treatment in XXXX : A Prospective Cohort Study.

@entity1 @entity28 @entity2299 @entity1089 @entity413 @entity165 @entity1090
OBJECTIVE: To determine the risk of developing @entity28 and related metabolic complications in @entity1 following long-term treatment with @entity1090 or @entity1089 . METHODS: This was a 1-year naturalistic longitudinal study conducted between February 2009 and March 2012. A total of 130 @entity1 aged 2 to 18 years without prior exposure to second-generation antipsychotics (SGAs) were enrolled at initiation of treatment with either @entity1090 or @entity1089 . Metabolic parameters were measured at baseline and months 6 and 12. Data of 37 @entity1 (20 treated with @entity1090 and 17 treated with @entity1089 ) who completed 12-month monitoring were used in the analysis. RESULTS: After 1 year of SGA treatment, mean weight increased significantly by 10.8 kg (95% CI 7.9 kg to 13.7 kg) for @entity1090 and 9.7 kg (95% CI 6.5 kg to 12.8 kg) for @entity1089 . Body mass index z score also increased significantly in both groups (P < 0.001). There was a high incidence of @entity1 becoming overweight or @entity28 (6/15 [40.0%] for @entity1090 -treated and 7/14 [50.0%] for @entity1089 -treated). The mean levels of fasting @entity413 (for @entity1090 -treated) and ratio of total @entity165 to high-density lipoprotein @entity165 (for @entity1089 -treated) increased significantly by 0.23 mmol/L (95% CI 0.03 mmol/L to 0.42 mmol/L) and 0.48 mmol/L (95% CI 0.15 mmol/L to 0.80 mmol/L), respectively. CONCLUSION: @entity1 treated with @entity1090 or @entity1089 are at a significant risk for developing @entity28 , elevated waist circumference, and @entity2299 during 12 months of treatment. These data emphasize the importance of regular monitoring for early identification and treatment of metabolic side effects.
